ETHICAL BALANCE ON CONDUCTING SPONSORED RESEARCH IN UNEQUAL SOCIAL, ЕСОNOMIС AND REGULATORY CONDITIONS



Cite item

Full Text

Abstract

Abstract

The modern concept of international clinical trials (CT) has reached strict regulation in terms of norms and ethics and is convincingly reflected in a series of current legislative acts, at the global, regional and national levels [2,3,7,8,10-13,23,32]. Of particular interest in this area are situations of dual loyalty related to moral, financial and legal gradation of research in countries with different levels in economic development and priorities for owning the investigational drug’s patent. Based on this, the new picture of the modern Russia geopolitical map on participation in international research requires adapting and revisiting the series of semantic characteristics. First of all, this concerns a fundamental change in Russia’s status that developed from a region for conducting research on foreign drugs to be further registered, to the position as the sponsor of research on domestic drugs in third countries, usually with limited economic and infrastructural resources. This metamorphosis is not only significant in terms of the qualitative redistribution of roles, but, in connection with the high rates of popularization and real increase in the volume of such research, for example, in Africa, it dictates a need to rethink the entire system of administrative and ethical approaches to their implementation. In this article, a targeted attention is first paid to the factor of special responsibility for the adoption and regulatory consolidation in the Russia the special ethical code for sponsor’s research in the context of their implementation in regions with limited resources. This task is coupled to introducing domestic experience as well as deep legal and information baggage accumulated by international practice into the protocol for the development of sponsor research in the Russia. The specificity is also of special importance because this work consists of the direct authorial involvement in the process for establishing and forming partnership ethical code based on the principles of justice, respect, care and honesty in research with unequal resources.

About the authors

Olga Kubar

St.Petersburg Pasteur Institute

Author for correspondence.
Email: okubar@list.ru

PhD, principal scientists in laboratory of etiology and control of viral infections

Россия, 197101, Russia, St.Petersburg, Mira st.14

References

  1. Гинзбург А.Л. Центр им. Гамалеи заявил о готовности поставлять странам Африки вакцины. // ТАСС. Саммит Россия – Африка. 28.07.2023., доступен на: https://tass.ru/obschestvo/18394227
  2. ГОСТ Р. 1.0-2004. Национальный стандарт Российской Федерации. Стандартизация в Российской Федерации. Основные положения" (утв. Приказом Ростехрегулирования от 30.12.2004. № 152-ст.).
  3. ГОСТ Р. 52379-2005. Национальный стандарт Российской Федерации. Надлежащая клиническая практика" (утв. Приказом Ростехрегулирования от 27.09.2005. № 232-ст.).
  4. Земсков Д.Н. Экспорт оригинальных препаратов позволит нам обеспечить и себя, и другие страны новыми эффективными лекарствами и развивать технологический суверенитет страны// "Иннопром". Приложение №123 от 11.07.2023, С. 4.
  5. Информационно – аналитический бюллетень № 29. 1 полугодие 2024., доступен на: http://acto-russia.org/files/bulletin_29.pdf
  6. Мурашко М. А. О перспективных направлениях для сотрудничества с африканскими странами // доступен на: https://minzdrav.gov.ru/news|2023|07|28.
  7. О техническом регулировании ФЗ РФ от 27 декабря 2002 г. № 184-ФЗ.
  8. (с изменениями на 2 июля 2021 года) (редакция, действующая с 23 декабря 2021 года).
  9. Об утверждении Правил надлежащей клинической практики Евразийского экономического союза. Решение Совета Евразийской экономической комиссии № 79 от 06.11.2016 // доступно на: www.consultant.ru
  10. Попова А.Ю. Россия и Африка: от помощи – к партнерству, российские медицинские лаборатории работают уже почти в 20 странах мира // доступно на: https://www.kp.ru/daily/27535.5/4801181/
  11. Правила проведения фарм.инспекций на соответствие GCP. Решение Совета Евразийской экономической комиссии № 66 от 06.11.2024 // доступно на: www.consultant.ru
  12. Трапкова А.А. Проведение фармацевтических инспекций на соответствие требованиям GCP ЕАЭС в Российской Федерации является осознанной необходимостью.// Безопасность и риск фармакотерапии. 2023. Т.11, № 2. С. 127-130.
  13. Хельсинская декларация. Принята на 18-й Генеральной ассамблее ВМА, Хельсинки, Финляндия, июнь 1964 г., последняя версия Бразилия, октябрь 2013 г.
  14. Этическая экспертиза биомедицинских исследований // Руководство для комитетов по этике. Под ред. А.Л.Хохлова. // Москва. 2021. 792 с.
  15. African Union. African Medicine Agency (AMA) Treaty | African Union. 2020. Available at: https://au.int/en/pressreleases/20200205/african-medicine-agency-ama-treaty. .
  16. Appiah D., Teye-Adjei D., Auagah C. Ethics Dumping: Case Studies from Global North and South Research Collaborations. [REVIEW] – Ethics. Journal of Multidisciplinary Research. 2024, vol. 2, no. 1. Available at:| www.Researchethics.In
  17. Bakani Mark Ncube, Admire Dube, Kim Ward // Establishment of the African Medicines Agency: progress, challenges and regulatory readiness // Journal of Pharmaceutical Policy and Practice. 2021, vol. 14, no. 1, - pp. 2-12/
  18. Bolstering Vaccine Manufacturing Capacity in Africa: A move towards self-sufficiency. The Brown Journal of Would Africa. 2020, vol. XXVIII, issue no. 1. Available at:| https://bjwa.brown.edu/28-1/bolstering-vaccine-manufacturing-capacity-in-africa-a-move-towards
  19. Chatfield K., Schroeder D., Guantai A., Bhatt K., Bukusi E., Odhiambo J-A., Cook J., Kimani J. Preventing ethics dumping: the challenges for Kenyan research ethics committees. Research Ethics. 2021, vol. 17, no. 1, pp. 23-44.
  20. COVID-19 pandemic in Africa. Available at: https://translated.turbopages.org/proxy_u/en-ru.ru.509a9cdb-6735ee35-93b48998 -74722d776562/https/en.wikipedia.org/wiki/
  21. Extraordinary Session of the IBC/Join Session of the IВС and IGBC/11th (Extraordinary) Session of COMEST. 23 and 24 February 2021. Available at: http://www.events.unesco.org
  22. Grietens K.P., Ribera J.M., Erhart A., Hoibak S., Ravinetto R.M., Gryseels C., Dierickx S., O'Neill S., Hausmann Muela S., D'Alessandro U. Doctors and Vampires in Sub-Saharan Africa: Ethical Challenges in Clinical Trial Research // Am J Trop Med Hyg. 2014, vol. 91, no. 2, pp. 213-215. Available at: doi: 10.4269/ajtmh.13-0630.
  23. Grüner S., Krüger F. The intention to be vaccinated against COVID-19: Stated preferences before vaccines were available. Appl. Econ. Lett. 2021, vol. 28, pp. 1847–1851. Available at: doi: 10.1080/13504851.2020.1854445.
  24. ICH harmonized guideline/ Integrated addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2). 2016. - Current step 4.
  25. Kelly A. The Territory of Medical Research: Experimentation in Africa’s Smallest State. Para states and medical research. Duke University Press., 2015. Chapter 10, pp. 304-332.
  26. Molyneux S., Geissler W. Ethics and the ethnography of medical research in Africa // Social Science & Medicine. 2008, vol. 67, no.5, pp. 685-695.
  27. Nachega J.B., Sam-Agudu N.A., Mellors J.W., Zumla A., Lynne M. Mofenson L.M. Scaling up Covid-19 vaccination in Africa — Lessons from the HIV Pandemic . - N Engl J Med. 2021, vol. 385, no. 3, pp. 196-198.
  28. Nature addresses helicopter research and ethics dumping Available at: https://www.nature.com/articles/d41586-022-01423-6.pdf
  29. Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines Regulation in Africa: current state and opportunities. Pharm Med. 2017, vol. 31, no. 6, pp. 383–397. Available at: doi: 10.1007/s40290-017-0210-
  30. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open. 2018, vol. 1, no. 4, e. 181662.
  31. Paul E., Steptoe A., Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. Lancet Reg. Health Eur. 2021, vol.1, 1000012. Available at: doi: 10.1016/j.lanepe.2020.100012.
  32. Schroeder D., Chatfield K., Chennells R., Herissone-Kelly P., Singh M. Equitable Research Partnerships: A Global Code of Conduct to Counter Ethics Dumping // Springer Verlag. 2019. 122 p.
  33. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. United States Government Printing Office. DHEW Publication No. (OS) 78-0012. -Bethesda, Md. -30.09. 1978. 20 p.
  34. World Health Organization. WHO | The African Regional Health Report: The health of the people. 2020. Available at: https://www.who.int/bulletin/africanhealth/en/. Accessed 25 Aug 2020.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Kubar O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies